Results from the T.E.S.T. compared to the lead compounds
Clusters
Bioconcentration factor1
Ames mutagenicity2
Oral rat LD503 [–Log10(moL/kg)]
48-hour T. pyriformis IGC504 (mg/L)
18, 1 of 1
19.08
Negative
373.49
N/A
23, 1 of 25
18.78
Negative
833.23
N/A
19, 1 of 5
39.65
N/A
839.23
N/A
4, 1 of 1
21.54
N/A
1,714.20
N/A
Compound 8A
12.25
Negative
881.07
N/A
Compound 8E
15.68
Negative
1,193.20
N/A
Compound 18
15.64
Positive
1,010.18
N/A
Compound 29
28.91
Positive
457.49
N/A
1 Bioconcentration factor: ratio of the chemical concentration in fish as a result of absorption via the respiratory surface to that in water at a steady state; 2 Ames mutagenicity: a compound is positive for mutagenicity if it induces revertant colony growth in any strain of Salmonella typhimurium; 3 Oral rat LD50: amount of chemical (mg/kg body weight) that causes 50% of rats to die after oral ingestion; 4 48-hour T. pyriformis IGC50: Concentration of the test chemical in water (mg/L) that causes 50% growth inhibition to Tetrahymena pyriformis after 48 hours. N/A: not applicable
Declarations
Acknowledgements
Thanks to Dr. Corinne Kay for her advice and support over the years and to Mr. Colin Gaudion for testing some of the programs used for this work.
Author contributions
AG: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Writing—original draft. UC: Writing—review & editing. Both authors read and approved the submitted version.
Conflicts of interest
The authors’ daughter, Isabella, was diagnosed with NBS4 in January 2003. Isabella relapsed in March 2005 and died in July 2005, a week after her seventh birthday.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Paraboschi I, Privitera L, Kramer-Marek G, Anderson J, Giuliani S. Novel Treatments and Technologies Applied to the Cure of Neuroblastoma.Children (Basel). 2021;8:482. [DOI] [PubMed] [PMC]
Gerges A, Canning U. Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review.ChemMedChem. 2024;19:e202300535. [DOI] [PubMed]
Kumalo HM, Bhakat S, Soliman MES. Theory and applications of covalent docking in drug discovery: merits and pitfalls.Molecules. 2015;20:1984–2000. [DOI] [PubMed] [PMC]
Mora J. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.Expert Rev Clin Pharmacol. 2016;9:647–53. [DOI] [PubMed]
Bhoopathi P, Mannangatti P, Emdad L, Das SK, Fisher PB. The quest to develop an effective therapy for neuroblastoma.J Cell Physiol. 2021;236:7775–91. [DOI] [PubMed]
Pennington B, Ren S, Barton S, Bacelar M, Edwards SJ. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2019;37:985–93. [DOI] [PubMed]
Roskoski R Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.Pharmacol Res. 2015;94:9–25. [DOI] [PubMed]
Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, et al. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.J Med Chem. 2015;58:347–61. [DOI] [PubMed]
Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy.Anticancer Agents Med Chem. 2009;9:66–76. [DOI] [PubMed]
Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer.Curr Opin Pharmacol. 2008;8:427–32. [DOI] [PubMed]
Grant S, Dent P. Kinase inhibitors and cytotoxic drug resistance.Clin Cancer Res. 2004;10:2205–7. [DOI] [PubMed]
Radi M, Brullo C, Crespan E, Tintori C, Musumeci F, Biava M, et al. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.Bioorg Med Chem Lett. 2011;21:5928–33. [DOI] [PubMed]
Schenone S, Zanoli S, Brullo C, Crespan E, Maga G. Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family.Current Drug Therapy. 2008;3:158–76. [DOI]
Vitali R, Mancini C, Cesi V, Tanno B, Piscitelli M, Mancuso M, et al. Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.Int J Cancer. 2009;125:2547–55. [DOI] [PubMed] [PMC]
Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors.Oncologist. 2009;14:667–78. [DOI] [PubMed] [PMC]
Kruewel T, Schenone S, Radi M, Maga G, Rohrbeck A, Botta M, et al. Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.PLoS One. 2010;5:e14143. [DOI] [PubMed] [PMC]
Lovera S, Sutto L, Boubeva R, Scapozza L, Dölker N, Gervasio FL. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation.J Am Chem Soc. 2012;134:2496–9. [DOI] [PubMed]
Lin Y, Roux B. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.J Am Chem Soc. 2013;135:14741–53. [DOI] [PubMed] [PMC]
Lin Y, Meng Y, Huang L, Roux B. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.J Am Chem Soc. 2014;136:14753–62. [DOI] [PubMed] [PMC]
Meng Y, Lin Y, Roux B. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases.J Phys Chem B. 2015;119:1443–56. [DOI] [PubMed] [PMC]
Redavide E. Role of an N2-Src-COPII pathway in neuroblastoma differentiation [dissertation]. University of York; 2018.
Molinari A, Fallacara AL, Maria SD, Zamperini C, Poggialini F, Musumeci F, et al. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.Bioorg Med Chem Lett. 2018;28:3454–7. [DOI] [PubMed]
Jha V, Macchia M, Tuccinardi T, Poli G. Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.Cancers (Basel). 2020;12:2327. [DOI] [PubMed] [PMC]
le Maire A, Germain P, Bourguet W. Protein-protein interactions in the regulation of RAR-RXR heterodimers transcriptional activity.Methods Enzymol. 2020;637:175–207. [DOI] [PubMed]
Yin L, Shen H, Diaz-Ruiz O, Bäckman CM, Bae E, Yu S, et al. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.BMC Neurosci. 2012;13:120. [DOI] [PubMed] [PMC]
Mandili G, Marini C, Carta F, Zanini C, Prato M, Khadjavi A, et al. Identification of phosphoproteins as possible differentiation markers in all-trans-retinoic acid-treated neuroblastoma cells.PLoS One. 2011;6:e18254. [DOI] [PubMed] [PMC]
Chen M, Hsu S, Lin H, Yang T. Retinoic acid and cancer treatment.Biomedicine (Taipei). 2014;4:22. [DOI] [PubMed] [PMC]
Janesick A, Wu SC, Blumberg B. Retinoic acid signaling and neuronal differentiation.Cell Mol Life Sci. 2015;72:1559–76. [DOI] [PubMed] [PMC]
Lone AM, Dar NJ, Hamid A, Shah WA, Ahmad M, Bhat BA. Promise of Retinoic Acid-Triazolyl Derivatives in Promoting Differentiation of Neuroblastoma Cells.ACS Chem Neurosci. 2016;7:82–9. [DOI] [PubMed]
Lascio SD, Saba E, Belperio D, Raimondi A, Lucchetti H, Fornasari D, et al. PHOX2A and PHOX2B are differentially regulated during retinoic acid-driven differentiation of SK-N-BE(2)C neuroblastoma cell line.Exp Cell Res. 2016;342:62–71. [DOI] [PubMed] [PMC]
Zage PE. Novel Therapies for Relapsed and Refractory Neuroblastoma.Children (Basel). 2018;5:148. [DOI] [PubMed] [PMC]
Cui S, Wang Y, Wang Y, Tang X, Ren X, Zhang L, et al. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.Eur J Med Chem. 2019;179:470–82. [DOI] [PubMed]
Magalingam KB, Radhakrishnan AK, Somanath SD, Md S, Haleagrahara N. Influence of serum concentration in retinoic acid and phorbol ester induced differentiation of SH-SY5Y human neuroblastoma cell line.Mol Biol Rep. 2020;47:8775–88. [DOI] [PubMed]
Bayeva N, Coll E, Piskareva O. Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions.J Pers Med. 2021;11:211. [DOI] [PubMed] [PMC]
Engel J, Richters A, Getlik M, Tomassi S, Keul M, Termathe M, et al. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.J Med Chem. 2015;58:6844–63. [DOI] [PubMed]
Kleywegt GJ, Bergfors T, Senn H, Motte PL, Gsell B, Shudo K, et al. Crystal structures of cellular retinoic acid binding proteins I and II in complex with all-trans-retinoic acid and a synthetic retinoid.Structure. 1994;2:1241–58. [DOI] [PubMed]
Wang L-h, Evers A, Monecke P, Naumann T. Ligand based lead generation - considering chemical accessibility in rescaffolding approaches via BROOD.J Cheminf. 2012;4:O20. [DOI] [PMC]
McGann M. FRED and HYBRID docking performance on standardized datasets.J Comput Aided Mol Des. 2012;26:897–906. [DOI] [PubMed]
López-Ramos M, Perruccio F. HPPD: ligand- and target-based virtual screening on a herbicide target.J Chem Inf Model. 2010;50:801–14. [DOI] [PubMed]
Janowski PA, Moriarty NW, Kelley BP, Case DA, York DM, Adams PD, et al. Improved ligand geometries in crystallographic refinement using AFITT in PHENIX.Acta Crystallogr D Struct Biol. 2016;72:1062–72. [DOI] [PubMed] [PMC]
Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings.J Chem Inf Model. 2021;61:3891–8. [DOI] [PubMed] [PMC]
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.J Comput Chem. 2010;31:455–61. [DOI] [PubMed] [PMC]
Moitessier N, Pottel J, Therrien E, Englebienne P, Liu Z, Tomberg A, et al. Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods.Acc Chem Res. 2016;49:1646–57. [DOI] [PubMed]
Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking.J Med Chem. 2006;49:3315–21. [DOI] [PubMed]
Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands.Drug Discov Today. 2004;9:641–51. [DOI] [PubMed]
Li X, Li X, Liu F, Li S, Shi D. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist.J Med Chem. 2021;64:10581–605. [DOI] [PubMed]
Klebe G. From In Vitro to In Vivo: Optimization of ADME and Toxicology Properties. In: Klebe G, editor. Drug Design. Springer, Berlin: Heidelberg; 2024. pp. 291–308. [DOI]
